AIDS Drugs in Development
A to Z Drug Facts
| AIDS Drugs in Development |
Acquired Immunodeficiency Syndrome (AIDS) is an immunodeficiency state caused by an infection with the human immunodeficiency virus, HIV. There are several drugs being studied for HIV, AIDS, and AIDS-related illnesses. Listed above are some antiviral, cytokine, immunomodulating drugs, and vaccines currently undergoing clinical trials.
| AIDS Drugs in Development | |||
| Drug | Drug type | FDA status | Treatment sponsor |
| AIDS | |||
| ACT (activated cellular therapy) | other | Phase II | Neoprobe |
| Amprenavir (Agenerase) 1 and indinavir (Crixivan) 1 | protease inhibitor combination | Phase II | Vertex Pharmaceuticals/Kissei Pharmaceutical |
| Amprenavir (Agenerase) 1 and nelfinavir (Viracept) 1 | protease inhibitor combination | Phase II | Vertex Pharmaceuticals/Kissei Pharmaceutical |
| Amprenavir (Agenerase) 1 and saquinavir (Fortovase) 1 | protease inhibitor combination | Phase II | Vertex Pharmaceuticals/Kissei Pharmaceutical |
| Amprenavir (Agenerase), 1 zidovudine (Retrovir), 1 and lamivudine (Epivir) 1 | Second generation HIV protease inhibitor combination | Phase III | Vertex Pharmaceuticals/GlaxoWellcome |
| BMS-234475/CGP-61755 | nd2 | Phase I | Bristol-Myers Squibb |
| Cytolin | nontoxid AIDS monoclonal antibody | Phase I/II | CytoDyn Inc. |
| MDX-240 | virus-specific bispecific antibody | Phase I/II | Medarex Inc. |
| Trichosanthin (GLQ223; Compound Q) | antiviral | Phase II | Genelabs Technologies |
| Zidovudine1/Didanosine1 (Scriptene) | heterodimer | Phase II | IVX Bioscience Inc./SS Pharmaceuticals |
| Cachexia | |||
| Testosterone1 | anabolic steroid | Phase II | TheraTech |
| CMV infection | |||
| Benzimidavir (1263W94) | CMV-DNA inhibitor | Phase II | GlaxoWellcome |
| CMV retinitis | |||
| GEM 132 intravenous | hybrid antisense oligonucleotide | Phase II | Hybridon |
| GEM 132 intravitreal | hybrid antisense oligonucleotide | Phase II | Hybridon |
| GW275175 | CMV-DNA maturation inhibitor | Phase I | GlaxoWellcome |
| ISIS 13312 | second generation antisense compound | Phase I | Isis Pharmaceuticals |
| Valganciclovir (Cymeval) | antiviral | Phase III | Hoffman-LaRoche |
| Drug | Drug type | FDA status | Treatment sponsor |
| Dementia | |||
| Memantine | NMDA receptor antagonist/neuroprotective agent | Phase II | Neurobiological Technologies |
| Diarrhea | |||
| DEHOP (diethylhomospermine) | polyamine analogue/antidiarrheal agent | Phase II | SunPharm Corp. |
| Letrazurile | nd2 | Phase II | Janssen Pharmaceutica |
| Synsorb CD (due to Clostridium difficile) | gastrointestinal | Phase II | Synsorb Biotech |
| Genital herpes | |||
| Cidofovir gel (Forvade) | antiviral | Phase I/II | Gilead Sciences |
| HIV infection | |||
| ABT 378 | protease inhibitor combination | Phase II | Abbott Laboratories |
| Aldesleukin (Proleukin)1 interleukin-2 (IL-2) | interleukin | Phase III | Chiron |
| Ampligen | nucleic acid | Phase II | HemispheRx Biopharma Inc. |
| BCH 10652 | reverse transcriptase inhibitor | Phase II | BioChem Pharma |
| BMS 232632 | protease azapeptide inhibitor | Phase I | Bristol-Myers Squibb |
| BMS-234475 | second generation protease inhibitor | Phase II | Bristol-Myers Squibb |
| Calanolide A | NNRTI3 | Phase I/II | Sarawak MediChem |
| CS-92 | NRTI4 | Phase I/II | Triangle Pharmaceuticals |
| CTL (adoptive immunotherapy) | gene therapy | Phase I | Targeted Genetics |
| DAPD | purine dioxolane nucleoside | Phase I | Triangle Pharmaceuticals |
| DMP-266 | NNRTI3 | Phase III | DuPont Merck |
| DMP-450 | second generation protease inhibitor | Phase I/II | Triangle Pharmaceuticals |
| HIV Therapeutic | nd2 | Phase I | United Biomedical |
| HGP-30 and sargramostim1 | nd2 | Phase I | Cel-Sci Corp./Immunex Corp. |
| HIV-IT | nd2 | Phase II | Chiron Viagene |
| Indinavir (Crixivan in NanoCrystal formulation) | protease inhibitor | Phase II | NanoSystems LLC/Merck and Co. Inc. |
| Interferon alfa-n3 Alferon N1 injection | nd2 | Phase III | Interferon Sciences |
| Interleukin-10 (Tenovil) | immunoregulatory agent | Phase I | Schering-Plough Corp. |
| Iodenosine (f-ddA) | purine-based reverse transcriptase inhibitor | Phase II | NCI US Bioscience |
| Drug | Drug type | FDA status | Treatment sponsor |
| ISIS 5320 | nd2 | Phase I | Isis Pharmaceuticals, Inc. |
| Multikine | immunotherapeutic agent | Phase I | Cel-Sci Corp. |
| n-docosanol (Lidakol) | broad-spectrum antiviral | Phase II | Avanir Pharmaceuticals |
| Nevirapine (Viramune),1 zidovudine (Retrovir),1 and didanosine (Videx)1 | protease inhibitor/reverse transcriptase inhibitor/nucleoside analogue | Phase III | Boehringer Ingelheim Pharmaceuticals/Roxane Laboratories |
| NIBA | nd2 | Phase I | Octamer |
| PMPA (tenofovir dipivoxil) | nucleotide inhibitor | Phase II | Gilead Sciences |
| Pro 367 | radiolabeled universal antigen binding agent | Phase I/II | Progenics |
| Pro 542 | recombinant universal antigen binding agent; HIV attachment inhibitor | Phase I/II | Progenics |
| Pro 2000 gel | antiviral agent/microbicide | Phase I NIAID trial | Procept |
| Procaine HCl (Anticort)1 | nd2 | Phase II | Steroidogenesis Inhibitors International |
| Rev M10pol AS (HSC-1P) | nd2 | Phase I/II | Novartis |
| Saquinavir mesylate (Fortovase)1 in combination with ritonavir (Norvir)1 and either zidovudine (Retrovir)1 or lamivudine (Epivir)1 | protease inhibitor combination or protease inhibitor/reverse transcriptase inhibitor combination | Phase III | Hoffmann-LaRoche |
| Sargramostim1 (granulocyte macrophage colony stimulating factor; GM- CSF; Leukine) | colony stimulating factor | Phase III | Immunex |
| Savvy | vaginal gel microbicide and spermicide | Phase I/II | Biosyn |
| TAT antagonist | antiviral | Phase I/II | Hoffman-LaRoche |
| T-cell gene therapy | gene therapy | Phase II | Cell Genesys |
| Thymopentin (Timunox) | immunomodulator | Phase III | Immunobiology Research Institute |
| Tipranavir | nonpeptidic HIV protease inhibitor | Phase II | Pharmacia and Upjohn |
| Tirilazed Mesylate | protease inhibitor | Phase I/II | GlaxoWellcome |
| Tucaresol (immuno-potentiator) | immunomodulator/immunopotentiator | Phase II | GlaxoWellcome |
| Tumor necrosis factor (TNF) | antiviral | Phase I | Immunex |
| Zintevir (AR177) | integrase inhibitor | Phase I/II | Aronex |
| Drug | Drug type | FDA status | Treatment sponsor |
| HIV infection and AIDS | |||
| Abavca/Perthon | plant derivative | Phase I/II | Advanced Plant Pharmaceuticals |
| Abacavir sulfate (Ziagen)1 and amprenavir (Agenerase)1 | nucleoside analogue/protease inhibitor | Phase III | Vertex Pharmaceuticals/GlaxoWellcome |
| AG 1549 | NNRTI3 | Phase II | Agouron Pharmaceuticals |
| Atevirdine mesylate | NNRTI3 | Phase II/III | Pharmacia and Upjohn |
| Efavirenz (Sustiva),1 lamivudine (Epivir),1 and zidovudine (Retrovir)1 | NNRTI3 /nucleoside analogue/NRTI4 | Phase III | DuPont Pharmaceuticals |
| FTC, emtricitabine (Coviracil) | nucleoside analogue | Phase II/III | Triangle Pharmaceuticals |
| HMR 4004 | CD4-zeta gene-modified T-lymphocytes | Phase II | Hoechst-Marion Roussel |
| Inactivin (HE 200) | cellular energy regulators | Phase I | Hollis-Eden Pharmaceuticals |
| Interferon alfa-n3 (Alferon LDO)1 | cytokine | Phase I/II | Interferon Sciences |
| MKC-442 | NNRTI3 | Phase III | Triangle Pharmaceuticals |
| MPL | nd2 | Phase I/II | Ribi ImmunoChem Research |
| Probucol (Panavir) | antiviral | Phase II | Vyrex |
| PNU-140690 | protease inhibitor | Phase II | Pharmacia and Upjohn |
| T-20 | fusion inhibitor | Phase II | MiniMed/Trimeris |
| Zidovudine (Aztec) controlled-release | antiviral | Phase III | Verex |
| HIV wasting | |||
| Androderm1 | testosterone replacement | Phase III | SmithKline Beecham |
| Dihydrotestosterone gel (Androgel DHT) | steroid | Phase II | Unimed |
| Oxandrolone (Oxandrin) gel | steroid | Phase III | Bio-Technology |
| Thalidomide (Thalomid)1 | TNF-alpha selective inhibitor | Phase II | Celgene |
| Hodgkin’s lymphoma | |||
| Aldesleukin (Proleukin ; IL-2)1 | interleukin | Phase II (NCI trial) | Chiron |
| Kaposi’s sarcoma | |||
| 9-aminocamptothecin | topoisomerase I inhibitor | Phase II (NCI trial) | NCI |
| 9-cis-retinoic acid | nd2 | Phase I/II (NCI trial) | Ligand Pharmaceuticals |
| Alitretinoin (Panretin) oral | retinoic acid | Phase II/III | Ligand Pharmaceuticals |
| Cidofovir | antiviral | Phase I/II | Gilead Sciences |
| Drug | Drug type | FDA status | Treatment sponsor |
| COL-3 | nd2 | Phase I (NCI trial) | NCI |
| Interleukin-12 | interleukin | Phase I/II (NCI trial) | NCI |
| LIDAKOL (n-docosanol) | nd2 | Phase II | LIDAK Pharmaceuticals |
| Panretin and interferon | nd2 | Phase I/II | Ligand Pharmaceuticals |
| Phenylhydrazone | antiviral | Phase I | Dekk-Tec |
| SU5416 | angiogenesis inhibitor | Phase I/II | SUGEN |
| Thalidomide1 | cytokine-selective inhibitor | Phase II | Andrulis |
| Thalidomide1 | nd2 | Phase II (NCI trial) | NCI |
| Tretinoin (Atragen) | liposomal all-transretinoic acid | Phase II completed | Aronex Pharmaceuticals |
| Virulizin | macrophage activator | Phase I/II | Imutec Pharma |
| Lymphomas | |||
| Virulizin | macrophage activator | Phase I/II | Imutec Pharma |
| Mycobacterial infection | |||
| Amikasin (MiKasome) | nd2 | Phase II | NeXstar Pharmaceuticals |
| Mycobacterial avium complex | |||
| Rifalazil (PA-1648) | rifampin derivative | Phase II | PathoGenesis |
| Non-hodgkin’s lymphoma | |||
| 506478 prodrug of guanine | arabinoside | Phase I | GlaxoWellcome |
| DEHOP (diethylhomospermine) | polyamine analogue/antidiarrheal agent | Phase II | SunPharm Corp. |
| G3139 | antisense compound | Phase I/II | Genta |
| Gallium nitrate | nd2 | Phase II (NCI trial) | NCI |
| Humanized Mab LL2 (LymphoCide) | nd2 | Phase I/II | Immunomedics |
| Pentostatin (Nipent) | nd2 | Phase II | SuperGen |
| Tretinoin (Atragen) | liposomal all-transretinoic acid | Phase II | Aronex Pharmaceuticals |
| Progressive multifocal leukoencephalopathy (PML) | |||
| Topotecan | nd2 | Phase II | SmithKline Beecham |
| Vaccines | |||
| AIDS vaccine | multi-envelope HIV vaccine component | Phase I | St. Jude Children’s Research Hospital |
| ALVAC -120TMG (VCP205) | vaccine | Phase II | Pasteur Merieux Connaught |
| Genevax-HIV | vaccine | Phase I | Wyeth-Lederle |
| gp120 (Aidsvax) | vaccine | Phase III | VaxGen |
| HGP-30 W | HIV vaccine | Phase II | Cel-Sci Corp. |
| HIV vaccine | vaccine | Phase II | Pasteur Merieux Connaught/Chiron Corp. |
| Drug | Drug type | FDA status | Treatment sponsor |
| HIV-1 peptide vaccine | vaccine | Phase I (NCI trial) | NCI |
| Remune | vaccine | Phase III IV | Immune Response/Agouron Pharm |
| TBC-3B | vaccine | Phase I AIDS | Therion Biologics |
| Xerostomia | |||
| Interferon alpha (Veldona Lozenge) | natural human interferon-alpha | Phase II | Amarillo Biosciences |
Books@Ovid
Copyright © 2003 Facts and Comparisons
David S. Tatro
A to Z Drug Facts